Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Sep;46(9):2562-7.
doi: 10.1161/STROKEAHA.115.009656. Epub 2015 Aug 6.

Do Patient Characteristics Explain the Differences in Outcome Between Medically Treated Patients in SAMMPRIS and WASID?

Seemant Chaturvedi  1 , Tanya N Turan  2 , Michael J Lynn  2 , Colin P Derdeyn  2 , David Fiorella  2 , L Scott Janis  2 , Marc I Chimowitz  2 ; SAMMPRIS Trial Investigators
Affiliations
Meta-Analysis

Do Patient Characteristics Explain the Differences in Outcome Between Medically Treated Patients in SAMMPRIS and WASID?

Seemant Chaturvedi et al. Stroke. 2015 Sep.

Abstract

Background and purpose: The Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) medical group had a much lower primary end point rate than predicted from the preceding Warfarin Aspirin Symptomatic Intracranial Disease (WASID) trial. This result has been attributed to the aggressive medical therapy used in SAMMPRIS, but an alternative hypothesis is that SAMMPRIS patients were at lower risk. We undertook analyses to evaluate these competing hypotheses.

Methods: Using proportional hazards regression, we compared the SAMMPRIS primary end point between SAMMPRIS medical patients and WASID patients meeting the same qualifying criteria adjusted for confounding baseline characteristics.

Results: The unadjusted comparison of the SAMMPRIS primary end point showed a significantly higher risk for WASID patients (P=0.009, logrank test) with 12 month Kaplan-Meier estimates of 21.9% in WASID and 12.6% in SAMMPRIS and hazard ratio 1.9 (95% confidence interval =1.2-3.0). The analyses identified the following confounding factors that varied between the studies and that conferred a higher risk: lack of statin use at enrollment (hazard ratio =1.8, 95% confidence interval =1.1-2.9, P=0.027) that was more prevalent among WASID patients (39% versus 14%, P<0.0001) and prior infarcts in the territory of the symptomatic vessel (hazard ratio =1.8, 95% confidence interval =1.1-2.9, P=0.023) that was more prevalent among SAMMPRIS patients (34% versus 22%, P=0.015).The hazard ratio for WASID versus SAMMPRIS adjusted for these 2 characteristics was 1.9 (95% confidence interval =1.1-3.2).

Conclusions: After adjustment for confounding baseline characteristics, WASID patients had an almost 2-fold higher risk of the SAMMPRIS primary end point, which supports the hypothesis that the lower rate of the primary end point in the medical arm of SAMMPRIS compared with WASID patients was as a result of the aggressive medical management used in SAMMPRIS.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00576693.

Keywords: atherosclerosis; dyslipidemia; intracranial atherosclerosis; stroke; warfarin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier estimates of the cumulative probability of the SAMMPRIS primary endpoint for SAMMPRIS medical patients and WASID patients meeting SAMMPRIS eligibility criteria.
See this image and copyright information in PMC

References

    1. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. New England Journal of Medicine. 2011;365:993–1003. - PMC - PubMed
    1. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. New England Journal of Medicine. 2005;352:1305–1316. - PubMed
    1. Turan TN, Lynn MJ, Nizam A, Lane B, Egan BM, Le NA, et al. Rationale, design, and implementation of aggressive risk factor management in the stenting and aggressive medical management for prevention of recurrent stroke in intracranial stenosis (sammpris) trial. Circulation. Cardiovascular quality and outcomes. 2012;5:e51–60. - PMC - PubMed
    1. Chimowitz MI, Lynn MJ, Turan TN, Fiorella D, Lane BF, Janis S, et al. Design of the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis trial. Journal of stroke and cerebrovascular diseases: the official journal of National Stroke Association. 2011;20:357–368. - PMC - PubMed
    1. Wong KS, Li H. Long-term mortality and recurrent stroke risk among chinese stroke patients with predominant intracranial atherosclerosis. Stroke. 2003;34:2361–2366. - PubMed

Publication types

Associated data